John Schieszer

The multicenter, randomized REACH2 trial demonstrated that ruxolitinib is efficacious and safe for patients with aGVHD after allogeneic stem cell transplantation.

Men with metastatic castration-resistant prostate cancer and symptomatic bone metastases had longer survival times when they received radium-223 as first-line therapy compared with those who received the drug as third-line therapy.

A survey of patients and healthcare providers revealed gaps in discussions and documentation of fertility preservation options for young adult patients with cancer and potential barriers to overcome to improve this care.

Researchers suggest appropriate monitoring and use of standard treatment algorithms to identify and treat toxic effects after a rechallenge after irAEs in patients receiving ICI therapy.

The National Comprehensive Cancer Network offers guidelines designed to protect patients and nurses while continuing needed cancer care during the COVID-19 pandemic.

In a web-based survey, oncology nurses self-report on their ability to assess the nutritional status of pediatric patients and their confidence in their assessments.

Some US medical centers have canceled treatments and all centers have altered their policies and procedures out of precaution related to the COVID-19 pandemic.

The authors of new review say the results of the JCOG0401 trial suggest that standard hormonal therapy alone vs salvage radiotherapy is not an appropriate management strategy for recurrence after radical prostatectomy.

Although some patients with cancer are at higher risk of developing severe disease should they become infected, these experts suggest the precautions being given to the general population are sufficient — at least for now.

The bell-ringing ceremony at the end of cancer treatment can have very unintended effects on patients, even those who can look forward to a cancer-free life.